Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.53 |
| ▸ | GSPT1 | P15170 | 6/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.45 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.44 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26740562 | 0.90 | CRBN (0.51) | CRBNGSPT1CSNK1A1IKZF3IKZF2 | |
| SCHEMBL26740556 | 0.89 | CRBN (0.56) | CRBNGSPT1CSNK1A1IKZF3MAP1LC3B | |
| SCHEMBL26740597 | 0.88 | CRBN (0.56) | CRBNGSPT1CSNK1A1IKZF3CYP2C19 | |
| SCHEMBL26740450 | 0.88 | CRBN (0.56) | CRBNGSPT1CSNK1A1IKZF3CYP2C19 | |
| SCHEMBL29739492 | 0.88 | CRBN (0.56) | CRBNGSPT1CSNK1A1IKZF3CYP2C19 | |
| SCHEMBL26740619 | 0.87 | CRBN (0.55) | CRBNGSPT1CSNK1A1CYP2C19KCNH2 | |
| SCHEMBL29739711 | 0.87 | CRBN (0.58) | CRBNGSPT1CSNK1A1IKZF3CYP2C19 | |
| SCHEMBL26633377 | 0.87 | CRBN (0.58) | CRBNGSPT1CSNK1A1IKZF3CYP2C19 | |
| SCHEMBL29739425 | 0.86 | CRBN (0.52) | CRBNGSPT1CSNK1A1IKZF3MAP1LC3B | |
| SCHEMBL26740660 | 0.86 | CRBN (0.52) | CRBNGSPT1CSNK1A1IKZF3MAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | CRBN 113/4885GSPT1 4066/4885CSNK1A1 167/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CRBN 107/4885GSPT1 4046/4885CSNK1A1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.